The limitation of this study was the lack of induced sputum data before the introduction of anti-IL-5, as this would serve as a reference for the individual patient, and it would enable us to follow the dynamic of eosinophilia from the biologic naive airway toward early examination at 16 weeks of treatment. The gene discussed is IL5; the disease is Increased total eosinophil count.